Sonus Pharmaceutical - Worst Pharma Stocks of 2007

Company: Sonus Pharmaceutical
Starting stock price: $6.02
Ending stock price: $0.44
Percent Change: -92.69%

Details: Sonus was delivered a crushing blow in September. A Phase III study of the company's breast cancer therapy, Tocosol Paclitaxel, was found to be less effective and linked to more side effects than Taxol. Bayer Schering terminated it's partnership with Sonus on the drug in October. The company has since enlisted Ferghana Partners to help evaluate the company's "alternative strategies." Sonus has one other cancer drug in development.

Related Articles:
Sonus shares shattered on drug failure. Report
Sonus shares surge as FDA approves Phase III design. Report

Sonus Pharmaceutical - Worst Pharma Stocks of 2007
Read more on

Suggested Articles

Pfizer is doubling down on real-world data in HR-positive, HER2-negative breast cancer patients to boost its case for blockbuster Ibrance.

Sanofi, which has moved purposefully into high technologies to get more from its manufacturing, will lean even more on that strategy to save costs.

In a last-minute deal during North American trade talks, the Trump administration agreed to scrap rules protecting biologic drugs from copycat rivals.